To Target the Untargetable: Elucidation of Synergy of APR-246 and Azacitidine in TP53 Mutant Myelodysplastic Syndromes and Acute Myeloid Leukemia | Aplastic Anemia & MDS International Foundation Return to top.
  1. Education
  2. Research Articles
  3. To Target the Untargetable: Elucidation of Synergy of APR-246 and Azacitidine in TP53 Mutant Myelodysplastic Syndromes and Acute Myeloid Leukemia

To Target the Untargetable: Elucidation of Synergy of APR-246 and Azacitidine in TP53 Mutant Myelodysplastic Syndromes and Acute Myeloid Leukemia

Journal Title: 
Haematologica
Primary Author: 
David A Sallman
Author(s): 
David A Sallman
Original Publication Date: 
Monday, June 1, 2020
Full Article on PubMed: 
https://www.ncbi.nlm.nih.gov/pubmed/32482751/
Bone Marrow Disease(s): 
  • acute myeloid leukemia (AML)
  • myelodysplastic syndromes (MDS)
Share with addtoany.com.